The approved medication ruxolitinib dampens inflammatory responses to malaria and can enhance immune memory to the parasite in infected volunteers, supporting its potential as an adjunctive therapy to improve outcomes. #ScienceTranslationalMedicine https://scim.ag/44tu6TB
This week's issue of #ScienceTranslationalMedicine has arrived!
A transcriptional signature could inform smarter antibiotic use in newborns with sepsis, an approved medication boosts anti-malaria immunity in volunteers, and more. https://scim.ag/43PsmE6
Lots of follow up exciting immunology to come! Thanks to three big teams combined effort Bridget Barber and Chris Engwerda @qimrb.bsky.social and our team, now @burnetinstitute.bsky.social, plus Stanford HIMC and Gates Foundation Global Health Discovery Collaboratory, @mmv.org and others.
Type I IFN response to malaria, and excessive signalling induces Type I regulatory CD4 T cells. We tested whether targeting this signalling with a JAK inhibitor ruxolitinib could be a host directed therapy to boost immunity. Exciting results show reduced inflammation and evidence of increased memory
So pleased to share our study of a host-directed therapy to boost malaria immunity.
Adjunctive ruxolitinib attenuates inflammation and enhances immunity in volunteers experimentally infected with Plasmodium falciparum | Science Translational Medicine www.science.org/doi/10.1126/...
Excited to have our latest research published in @jem.org this week and also highlighted by @natrevimmunol.nature.com
@wehi-research.bsky.social @benjbroom.bsky.social
